Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 14,387 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Injectable Clear all
Completed Phase 3 Interventional Results available

Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects

NCT00840086
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A
Interventions
turoctocog alfa
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
12 Years to 65 Years · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
18
States / cities
Little Rock, Arkansas • Long Beach, California • Tampa, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2017 · Synced Oct 21, 2026, 6:53 AM EDT
Completed Phase 2 Interventional Results available

Selinexor (KPT-330) in Older Patients With Relapsed AML

NCT02088541
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML)
Interventions
Selinexor, Hydroxyurea, Ara-C
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
60 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
26
States / cities
Los Angeles, California • Sacramento, California • Stanford, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Oct 21, 2026, 6:53 AM EDT
Completed Phase 4 Interventional

Prospective, Randomized, Multi-center Clinical Study of Plasma Disc Decompression

NCT00189605
View directory record Official record
Conditions
Radicular Pain
Interventions
Perc-DLR/Perc-DLG, Fluoroscopy guided transforaminal epidural steroid injection (TFESI)
Device · Drug
Lead sponsor
ArthroCare Corporation
Other
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
13
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Napa, California + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2015 · Synced Oct 21, 2026, 6:53 AM EDT
Recruiting Phase 3 Interventional

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT07222566
View directory record Official record
Conditions
Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC), Metastatic Non Small Cell Lung Cancer, Lung Cancer
Interventions
PF-08634404, Pembrolizumab, Chemotherapy Regimen 1, Chemotherapy Regimen 2
Biological · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
226
States / cities
Bullhead City, Arizona • Chandler, Arizona • Gilbert, Arizona + 164 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 21, 2026, 6:53 AM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Evaluating the Safety and Immunogenicity of Polyvalent DNA and Recombinant gp120 Protein HIV Vaccine (PDPHV) in Healthy, HIV-uninfected Adults

NCT07675629
View directory record Official record
Conditions
HIV Prevention
Interventions
PDPHV Plasmid DNA Vaccines (env (A, B, C, A/E)/gag (C)), PDPHV Recombinant Protein Vaccines (gp120 (A, B, C, A/E)), Alhydrogel adjuvant, GLA-SE adjuvant, Placebo for DNA Vaccines, Protein Vaccines and Adjuvants
Biological
Lead sponsor
Worcester HIV Vaccine
Industry
Eligibility
18 Years to 55 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 21, 2026, 6:53 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

Repeat Antenatal Steroids Trial

NCT00015002
View directory record Official record
Conditions
Complications, Pregnancy
Interventions
Betamethasone
Drug
Lead sponsor
The George Washington University Biostatistics Center
Other
Eligibility
Female only
Enrollment
486 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2007
U.S. locations
19
States / cities
Birmingham, Alabama • Miami, Florida • Chicago, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 21, 2026, 6:53 AM EDT
Terminated Phase 2 Interventional Results available

Early Metabolic Resuscitation for Septic Shock

NCT03895853
View directory record Official record
Conditions
Multiple Organ Failure, Septic Shock, Severe Sepsis
Interventions
Best Practice, early metabolic resuscitation
Other · Dietary Supplement
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Oct 21, 2026, 6:53 AM EDT
Terminated Phase 2 Interventional Results available

Erenumab For Treatment of Hemicrania Continua

NCT04303845
View directory record Official record
Conditions
Hemicrania Continua
Interventions
Erenumab
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 66 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 17, 2023 · Synced Oct 21, 2026, 6:53 AM EDT
Active, not recruiting Phase 1 Interventional

Safety and Pharmacodynamics of GNSC-001 Intra-articular Injection for Knee Osteoarthritis

NCT05835895
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteo Arthritis Knee, Knee Osteoarthritis
Interventions
GNSC-001, transient immune-modulation, Placebo
Genetic · Drug
Lead sponsor
Genascence Corporation
Industry
Eligibility
40 Years to 75 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
9
States / cities
Mobile, Alabama • La Mesa, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2025 · Synced Oct 21, 2026, 6:53 AM EDT
Completed Phase 2 Interventional Results available

Envarsus XR in Lung Transplant

NCT04420195
View directory record Official record
Conditions
Lung Transplant
Interventions
Extended-Release Tacrolimus, Immediate-Release Tacrolimus
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 75 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 22, 2024 · Synced Oct 21, 2026, 6:53 AM EDT
Completed Phase 2 Interventional Results available

CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy

NCT02654977
View directory record Official record
Conditions
Familial Partial Lipodystrophy, Nonalcoholic Steatohepatitis, NAFLD
Interventions
Metreleptin
Drug
Lead sponsor
University of Michigan
Other
Eligibility
5 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Oct 21, 2026, 6:53 AM EDT
Completed Phase 2 Interventional Results available

Efficacy of Low Dose, SubQ Interleukin-2 (IL-2) to Expand Endogenous Regulatory T-Cells in Liver Transplant Recipients

NCT02739412
View directory record Official record
Conditions
Liver Transplantation
Interventions
Interleukin-2
Biological
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 21, 2026, 6:53 AM EDT
Completed Phase 3 Interventional

A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults

NCT06067230
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
mRNA-1345
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
32
States / cities
Glendale, Arizona • Phoenix, Arizona • Tempe, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 21, 2026, 6:53 AM EDT
Recruiting Phase 2 Interventional

ELISA in Relapsed/Refractory MM

NCT06832865
View directory record Official record
Conditions
Relapsed Refractory Multiple Myeloma (RRMM), Relapsed Refractory Multiple Myeloma
Interventions
elranatamab, Isatuximab SC, Isatuximab SC-OBDS
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 21, 2026, 6:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

VRC 320: A Phase I, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA090-00-VP, Administered Via Needle and Syringe or Needle-free Injector, PharmaJet, inHealthy Adults

NCT02996461
View directory record Official record
Conditions
Prevention of Zika Infection, Zika-Specific Immune Response
Interventions
VRC-ZKADNA090-00-VP
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 21, 2026, 6:53 AM EDT
Terminated Phase 2 Interventional Results available

Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For Collection and for Transplantation

NCT00396383
View directory record Official record
Conditions
Multiple Myeloma
Interventions
plerixafor
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 13, 2014 · Synced Oct 21, 2026, 6:53 AM EDT
Not listed No phase listed Observational

Injection of Autologous Bone Marrow Aspirate in Patients With Degenerative Disc Disease.

NCT05146583
View directory record Official record
Conditions
Lumbar Disc Disease
Interventions
Autologous bone marrow aspirate injected intradiscal after microdiscectomy, Discectomy only
Procedure
Lead sponsor
New York Presbyterian Hospital
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 21, 2021 · Synced Oct 21, 2026, 6:53 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Assess the Safety and Efficacy of AGN-151586 Injections for the Treatment of Moderate to Severe Forehead Lines (FHL) in Adult Participants

NCT07730554
View directory record Official record
Conditions
Forehead Lines
Interventions
AGN-151586
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
5
States / cities
Newport Beach, California • New York, New York • Wilmington, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 21, 2026, 6:53 AM EDT
Terminated Phase 4 Interventional

Continuous Transversus Abdominis Plane Nerve Block for Postoperative Analgesia

NCT00944151
View directory record Official record
Conditions
Incisional Pain
Interventions
TAP Catheter and Infusion of Study Solution
Procedure
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 21, 2026, 6:53 AM EDT
Not listed Phase 1 Interventional

Safety Study to Test the Safety of HspE7 and Poly-ICLC Given in Patients With Cervical Intraepithelial Neoplasia

NCT00493545
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia
Interventions
HspE7 and Poly-ICLC
Biological
Lead sponsor
Nventa Biopharmaceuticals Corporation
Industry
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
8
States / cities
Los Angeles, California • San Diego, California • Augusta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated May 7, 2008 · Synced Oct 21, 2026, 6:53 AM EDT
Terminated Phase 1 Interventional Results available

A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma

NCT02082977
View directory record Official record
Conditions
Cancer, Neoplasms
Interventions
GSK2816126
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Oct 21, 2026, 6:53 AM EDT
Completed Phase 3 Interventional

Hymovis™ Versus Placebo in Knee Osteoarthritis

NCT01372475
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Hymovis Intra-articular Injection, Phosphate Buffered Saline Injection
Device · Procedure
Lead sponsor
Fidia Farmaceutici s.p.a.
Industry
Eligibility
40 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
32
States / cities
Birmingham, Alabama • Tucson, Arizona • Encinitas, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Oct 21, 2026, 6:53 AM EDT
Completed Phase 2 Interventional Results available

P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)

NCT02633501
View directory record Official record
Conditions
CNS Lesion, Blood Brain Barrier Defect
Interventions
P03277, Gadobenate dimeglumine, MRI
Drug · Device
Lead sponsor
Guerbet
Industry
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
10
States / cities
Chicago, Illinois • Boston, Massachusetts • Farmington Hills, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Oct 21, 2026, 6:53 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI

NCT03153319
View directory record Official record
Conditions
Mucopolysaccharidosis I, Mucopolysaccharidosis II, Mucopolysaccharidosis VI
Interventions
Adalimumab Injection [Humira], Saline Solution for Injection
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
5 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 21, 2026, 6:53 AM EDT